Medicsen: non-invasive, artificial pancreas, predictive AI

Non-invasive artificial pancreas for diabetes using predictive AI and needle-free automatic drug delivery.

In 2015, a little girl with diabetes rejected the treatment during my medical consult. The young girl had to adapt her daily routine to the disease, as far as avoiding birthday parties. She and her mother were constantly worried about the impact of this disease on daily routines. This is what we want to solve, by removing the constant use of needles and liberating patients from the daily burdens of Type 1 diabetes.

Currently, there are 425M people with diabetes worldwide and only 35% of patients achieve their target goals. Medicsen has developed and patented a non-invasive artificial pancreas for diabetes using predictive AI and needle-free automatic drug delivery. This hardware device is compatible with our software; a lifestyle coach based on future glucose prediction, chatbot interface, automatic data collection and behavior intervention.

Our learning algorithm in the cloud receives information from third-party wearables patients currently use (continuous glucose monitors, smartwatches). The chatbot app then shows the predicted glucose levels for the next hour, recommended actions to avoid any risk, and personalized recipes and activity plans to improve glucose performance in their daily lives.  It answers questions like: What happens if I drink a coke in 30 minutes? What if I go for a 1 hour hike? showing the predicted levels and recommended actions to avoid risks. It has less than 5mg/dl as error on 90 minutes glucose forecast

We are committed to supporting each other as we embark on our mission to provide excellent diabetes care for our patients, their families and carers, and people who are at risk. We believe our efforts to introduce the automatic needle-free revolution will empower individuals to regain greater control of their health and lives. 

There are several direct competing solutions on the market for diabetes: invasive artificial pancreas, insulin pumps, insulin pens, glucometers, APPs and CGMs. Each of these solutions can be costly, inconvenient, invasive or lack personalization. 

The market is moving towards more personalized, self-managed and preventive health. In addition to our needle-free technology, Medicsen's competitive edge is defined by advanced characteristics:
- Personalization: based on individual parameters
- Peace of mind: the system takes care of everything
- Reliable: based on the most recent scientific evidence 
- Enabling: predictions and advice reduce uncertainty 
- Easy to use: chatbot interface increases treatment adherence

Medicsen provides non-invasive digital therapies tailored to each patient and its current context by interconnecting hardware and software components. We aim to provide the necessary change in the structure of treating chronic diseases, leading the transformation movement towards personalized telemedicine, thereby improving control and reducing spending on common pathologies such as diabetes, cardiovascular diseases, and obesity. As such, Medicsen positions itself around telemonitoring, artificial intelligence, personalization, and non-invasive drug delivery to standardize this method for the treatment of other pathologies and develop technological solutions to shape the path of chronic disease therapies.

1. Access funding in order to further expedite the commercialization process for the non-invasive artificial pancreas. This will involve finalizing our regulatory and strategic plans.
2. Enhance technology: adapt and fine-tune the functionalities of each component of the App;
3. Build further alliances and reach key agreements with partners in priority markets to ensure scalability and sustainability.

Eduardo 3-5 years?

X

X

X

More than 20 team members are involved in the development of our solution. Team experience includes ex-NASA, ex-Pfizer, TR35, university professors, active investors, medical doctors, diabetic patients and entrepreneurial leaders. Team members bring experience and knowledge from various fields: biology, healthcare, telecommunications, HW and SW engineering, biochemistry, materials, artificial intelligence, and business (pharma, tech).

We are aware of and acknowledge the inequalities in health experienced across the globe, today. We are committed to supporting each other as we embark on our mission to provide excellent diabetes care for our patients, their families and carers, and people who are at risk.

B2B model with the app as patient support program in the Pharma and hospital industries. A patient support program beyond the pill. 

Yearly license fee for implementation of subscription packages fee + data license and development for adaptation.

Individual agreements that take around 6 months to close

Medicsen aims to be the leaders in shaping the future of digital health. We believe Solve will enable our efforts to transform the healthcare landscape towards digitalization, improve the health sector and the quality of life with it while decreasing costs.

Medicsen aims to reduce the impact of chronic disease worldwide by changing the future of healthcare through digitalization of services. Key barriers include possible competitors who may be designing a similar or substitutive device; high start-up costs involved in setting up eHealth systems; regional differences in accessing ICT, limited access in deprived areas; and inadequate or fragmented legal frameworks.